Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1

被引：75

作者：

Riddle, MC

Drucker, DJ

机构：

[1] Univ Toronto, Toronto Gen Hosp, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada

[2] Univ Toronto, Toronto Gen Hosp, Dept Med, Toronto, ON M5G 2C4, Canada

[3] Oregon Hlth & Sci Univ, Div Endocrinol Diabet & Clin Nutr, Sect Diabet, Portland, OR 97201 USA

来源：

DIABETES CARE | 2006年 / 29卷 / 02期

关键词：

D O I：

10.2337/diacare.29.02.06.dc05-1267

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：435 / 449

页数：15

共 188 条

[51] Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].

Edwards, CMB ;

Todd, JF ;

Mahmoudi, M ;

Wang, ZL ;

Wang, RM ;

Ghatei, MA ;

Bloom, SR .

DIABETES, 1999, 48 (01) :86-93

[52] Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects [J].

Elbrond, B ;

Jakobsen, S ;

Larsen, S ;

Agerso, H ;

Jensen, LB ;

Rolan, P ;

Sturis, J ;

Hatorp, V ;

Zdravkovic, M .

DIABETES CARE, 2002, 25 (08) :1398-1404

[53] PLASMA INSULIN RESPONSE TO ORAL + INTRAVENOUS GLUCOSE ADMINISTRATION [J].

ELRICK, H ;

HLAD, CJ ;

ARAI, Y ;

STIMMLER, L .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1964, 24 (10) :1076-+

[54]

ENG J, 1992, J BIOL CHEM, V267, P7402

[55] Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets [J].

Farilla, L ;

Bulotta, A ;

Hirshberg, B ;

Calzi, SL ;

Khoury, N ;

Noushmehr, H ;

Bertolotto, C ;

Di Mario, U ;

Harlan, DM ;

Perfetti, R .

ENDOCRINOLOGY, 2003, 144 (12) :5149-5158

[56] The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type I diabetes [J].

Fineman, MS ;

Koda, JE ;

Shen, LZ ;

Strobel, SA ;

Maggs, DG ;

Weyer, C ;

Kolterman, OG .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (05) :636-641

[57] POSTPRANDIAL HYPERGLYCEMIA IN PATIENTS WITH NONINSULIN-DEPENDENT DIABETES-MELLITUS - ROLE OF HEPATIC AND EXTRAHEPATIC TISSUES [J].

FIRTH, RG ;

BELL, PM ;

MARSH, HM ;

HANSEN, I ;

RIZZA, RA .

JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (05) :1525-1532

[58] The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans [J].

Flint, A ;

Raben, A ;

Rehfeld, JF ;

Holst, JJ ;

Astrup, A .

INTERNATIONAL JOURNAL OF OBESITY, 2000, 24 (03) :288-298

[59] Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes [J].

Gault, VA ;

Irwin, N ;

Green, BD ;

McCluskey, JT ;

Greer, B ;

Bailey, CJ ;

Harriott, P ;

O'Harte, FPM ;

Flatt, PR .

DIABETES, 2005, 54 (08) :2436-2446

[60] Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats [J].

Gedulin, BR ;

Smith, P ;

Prickett, KS ;

Tryon, M ;

Barnhill, S ;

Reynolds, J ;

Nielsen, LL ;

Parkes, DG ;

Young, AA .

DIABETOLOGIA, 2005, 48 (07) :1380-1385

← 1 2 3 4 5 6 7 8 9 10 →